ATL 101 - Telix Pharmaceuticals

Drug Profile

ATL 101 - Telix Pharmaceuticals

Alternative Names: 177Lu-J591; 90Y-J591; Anti-PSMA monoclonal antibody J591; huJ 591; J 591; Lu-177-J591; Lutetium-177-labelled anti-PSMA monoclonal antibody J591; MLN 591RL; MLN591; Monoclonal antibody J591; muJ591; Radiolabelled J591; Radiolabelled MLN591

Latest Information Update: 12 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cornell University
  • Developer BZL Biologics; Weill Cornell Medical College
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • No development reported Solid tumours

Most Recent Events

  • 10 Sep 2018 ATLAB Pharma has been acquired by Telix Pharmaceuticals
  • 28 Aug 2018 No recent reports of development identified for phase-I development in Prostate-cancer(Late-stage disease, Metastatic disease) in USA (IV, Infusion)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top